Figure 4
From: A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma
Effects of the anti-IL4Rα-NPs on lung inflammatory cell activation and function in the treated mice. (a) CD69 expression level on CD3 cells in the lung tissue before and after the anti-IL4Rα-NP treatment. Representative FACS data showing a decrease in CD69 expression following treatment with the anti-IL4Rα-NPs. (b) Effect of the anti-IL4Rα-NP treatment on the proliferative ability of CD4 and CD8 T cells in response to OVA stimulation. CD4 and CD8 cells isolated from the lungs of mice treated with or without the anti-IL4Rα-NPs were stimulated with OVA for 2 days. The Ki-67 levels were determined using FACS analysis. Representative FACS data showing the decrease in Ki-67 expression in CD4 cells following treatment with the anti-IL4Rα-NPs. (c, d) CD4 and CD8 cells isolated from the lungs of mice treated with or without the anti-IL4Rα-NPs cells were stimulated with OVA and the frequency of cells producing IL-4, IL-5, TNF-α and IFN-γ was determined using FACS analysis. Representative FACS data showing the decrease in CD4 cells expressing IL-4 following treatment with anti-IL4Rα-NPs. (e) Frequencies of neutrophils and eosinophils isolated from the lungs of mice treated with or without anti-IL4Rα-NPs. (*) for control vs OVA, **P<0.01, ***P<0.001; (#) for OVA vs anti-IL4Rα-NPs, #P<0.05, ##P<0.01, ###P<0.001.
